Compare Gilead Sciences, Inc. (GILD) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sibanye Stillwater Ltd — how do they compare? Gilead Sciences, Inc. trades at $134.78 (market cap $163.51B), while Sibanye Stillwater Ltd trades at $8.09 (market cap $5.93B). The key difference: Gilead Sciences, Inc. is far larger — about 27.6× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| GILD | SBSW | |
|---|---|---|
Market Cap | $163.51B | $5.93B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $21.12 |
52-Week Low | $108.22 | $7.27 |
Enterprise Value | $178.05B | $7.56B |
Dividend Yield | 2.49% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Sibanye Stillwater (SBSW) trades at $8.12, down 5.25% today, reflecting ongoing challenges despite a low P/E of 4.76 and P/S of 0.77. The stock shows bearish technical signals with key support at $8, while fundamentals reveal negative net income margins and ROE. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, yet earnings misses in recent quarters underscore persistent profitability issues.
The outlook is mixed: deep valuation discounts and analyst consensus targets near $14.25 suggest upside potential, but risks from volatile commodity prices, high debt, and inconsistent earnings warrant caution. Investors should weigh the turnaround narrative against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
